HDAC6-IN-53

• Description:

  HDAC6-IN-53 (Compound W28) is an inhibitor targeting histone deacetylase 6 (HDAC6) with an IC50 of 19.65 nM. HDAC6-IN-53 exerts the activity of inhibiting the phenotype of idiopathic pulmonary fibrosis (IPF) by suppressing the collagen expression induced by TGF-β1, and it has demonstrated a good therapeutic effect in a mouse model of pulmonary fibrosis induced by bleomycin (HY-108345) . HDAC6-IN-53 can be used in the research of idiopathic pulmonary fibrosis and other related pulmonary fibrosis diseases.

• UNSPSC:

  12352005

• Target:

  HDAC

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Inflammation/Immunology

• Smiles:

  O=C(C1=CC=C(Br)C=C1)NCCC2=CN(CC3=CC=C(C(NO)=O)C=C3)C4=CC=C(OC)C=C42

• Molecular Formula:

  C26H24BrN3O4

• Molecular Weight:

  522.39

• References & Citations:

  [1]Quan J, et al. Discovery of novel selective HDAC6 inhibitors via a scaffold hopping approach for the treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo. Bioorg Chem. 2025 Mar 11;159:108360.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  HDAC6

• CAS Number:

  [3081880-03-4]